Dr. Quon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
403 W Adams Blvd
Hemophilia Treatment Center
Los Angeles, CA 90007Phone+1 213-742-1000Fax+1 213-742-1103
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2003- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1996 - 1999
David Geffen School of Medicine at UCLAClass of 1996
Certifications & Licensure
CA State Medical License 1998 - 2025- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
Clinical Trials
- Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A Start of enrollment: 2013 Mar 01
- Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B Start of enrollment: 2013 Feb 11
- Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- 178 citationsSafety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsJerry S. Powell, Neil C. Josephson, Doris Quon, Margaret V. Ragni, Gregory Cheng
Blood. 2012-03-29 - 52 citationsRecombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levelsA. Shapiro, Margaret V. Ragni, Roshni Kulkarni, J. Oldenberg, A. Srivastava
Journal of Thrombosis and Haemostasis. 2014-11-01 - 45 citationsTwo-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.Johnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, Susan Shapiro, Sheng-Chieh Chou
The New England Journal of Medicine. 2023-02-23
Journal Articles
- BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia ADoris V Quon, Margaret V Ragni, The New England Journal of Medicine
- Development and Reliability of the Joint Tissue Activity and Damage Examination for Quantitation of Structural Abnormalities by Musculoskeletal Ultrasound in Hemophili...Eric Y Chang, Annette von Drygalski, Doris V Quon, Tudor H Hughes, Journal of Ultrasound in Medicine
Press Mentions
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AJanuary 2nd, 2020
Clinical Challenge: From Pediatric to Adult Hemophilia CareDecember 17th, 2019
California's Most Expensive Patient in Recent Years Has HemophiliaMarch 6th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
